USPTO Patents Application 10066009

02/17/2005 15:44 FAX 650 324 0638

HELLER EHRMAN

1002

Amendments to the Claims :

1. (canceled)

2. (previously presented) A crystal formed by insulin-like growth factor- 1 (IGF-1) of SEQ
ID NO: 1 that diffracts x-ray radiation to produce a diffraction pattern representing the
three-dimensional structure of the IGF-1, and has approximately the following cell
constants a=3 1.831 A, 6=71.055 A, c=65.995 A, and a space group of C222i, and a=p=y.

3. (previously presented) The crystal of claim 2 wherein the IGF-1 contains an A-, B-, C-,
and D-region and forms a dimer in the crystal and wherein the crystal comprises a
receptor binding site at the dimer interface.

4. (previously presented) A composition comprising the crystal of claim 2 and a canier.

5. (original) The composition of claim 4 wherein the IGF-1 is biologically active when

resolubilized.
6-8. (canceled)

9. (currently amended) A method of crystallizing insulin-like growth factor-1 (IGF-1) of
SEQ ID NO: 1 comprising the steps of:

(a) mixing (1) an aqueous solution comprising said IGF-1 , sodium chloride and
sodium acetate, obtained by dilution of an IGF-1 solution in a mixture of about 0.15 M
sodium chloride and about 20 mM sodium acetate (pH 4.5X m up to a final IGF-1
concentration of about 1 to 50 5 to 15 mg/m^ with (2) a reservoir solution comprising - a
pr e cipitant selected from the group consisting of about 24% polyethylene glycol 3350
buffered to about pH 6.5 with about 0.1 M sodium cacodvlate and about 14 mM N. N-
bis(3-D-gluconaiiudopropvl>deoxvcholamine. as a detergent , in a ratio of about 4:5
sodium citrat e , ammonium s ulfate, sodium oacodylat e , and a mixtur e thereof , to form a
mixed volume; and

(b) allowing said mixed volume to equilibrate over said reservoir solution until small
crystals with a plate-like morphology appear in about 4 to 5 days:

(c) adding methyl pentanediol to a final concentration of about 20%: and

(b) ( d) crystallizing recrystallizing the mixed, volume mixture to yield IGF- 1 crystals
that diffract x-ray radiation to produce a diffraction pattern representing the three-

PAGE 2/5 * RCVD AT 2/17/2005 6:35:14 PM [Eastern Standard Time] * SVR:USPTO-EFXRF-1/26 * DNIS:2730934 * CSID:650 324 0638 * DURATION (mm-ss):02-00

02/17/2005 15:45 FAX 650 324 0638

HELLER EHRMAN

@003

dimensional structure of the IGF-1, and have approximately the following cell constants
a=31.831 A, 6=71.055 A, c=65.995 A, and a space group of C222i, and a=p=y .

10. (original) The method of claim 9 wherein the IGF-1 is obtained from a prokaryotic cell.

11. -20. (canceled)

21 . (currently amended) The method of claim 9 wherein the equilibration in step (b) is
carried out by vapor diffusion crystallization, batch crystallization, liquid bridge
crystallization, or dialysis crystallization.

22. (currently amended) The method of claim 9 wherein the equilibration in step (b) is
carried out by vapor diffusion crystallization.

23. -26. (canceled)

27. (currently amended)* Crystalline insulin-like growth factor-1 (IGF-1) produced by the

method of claim 26 9.
28-34. (canceled)

35. (previously presented) A co-crystalline complex of crystals of insulin-like growth factor-
1 (IGF-1) of SEQ ID NO: 1 having approximately the following cell constants a=31.831
A, 6=71.055 A, c=65.995 A, and a space group of C222i, and oc=P=y, and N, N-bis(3-D-
gluconamidopropyl)-deoxycholamine.

36. (previously presented) A method for determining a three-dimensional structure of IGF-1
of SEQ ID NO: 1 comprising:

(a) crystallizing the IGF-1;

(b) irradiating the crystalline IGF-1 to obtain a diffraction pattern characteristic of the
crystalline IGF-1, wherein the crystalline IGF-1 has approximately the following cell
constants a=31.831 A, 6=71.055 A, c==65.995 A, and a space group of C222 b and a=P=y;
and

(c) transforming the diffraction pattern into the three-dimensional structure of the IGF-1 .
37-48. (canceled)

49. (currently amended) A heavy-atom derivative of ef the crystalline IGF-1 of claim 2.

50. (canceled)

PAGE 3/5 * RCVD AT 2/17/2005 6:35:14 PM [Eastern Standard Time] * SVR:USPTO-EFXRF-1/26 * DNJS:2730934 ■ CSID:650 324 0638 * DURATION (mm-ss):02-00